India Panel Favors Favipiravir, Tocilizumab As It Assesses COVID-19 Treatments
Strides Begins Favipiravir Exports, Glenmark to Start Trials
Executive Summary
In a preliminary assessment of repurposed COVID-19 treatments by a government-appointed panel to assess the readiness and potential of a drug to be used in India, favipiravir and tocilizumab have emerged as front-runners. With Strides Pharma exporting the antiviral and Glenmark set to begin clinical trials, even the industry is supporting favipiravir, which is already in studies in Japan and China.